Vitamin B1-containing oral liquid composition

Abstract

To provide an oral liquid composition containing vitamin B1 or a derivative thereof or salts thereof, the composition showing a reduction in vitamin B1-derived unpleasant odor.SOLUTION: An oral liquid composition contains a vitamin B1, and at least one selected from the group consisting of galangal extract and mango leaf extract .SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to an oral liquid composition containing vitamin B1 or its derivative or their salts. More specifically, it relates to an oral liquid composition with reduced unpleasant odor derived from vitamin B1 or its derivative or their salts.

Background Art

[0002] Vitamin B1 or its derivative or their salts (hereinafter also referred to as "vitamin B1s") are known as nutrients necessary for maintaining the body's functions. When deficient, symptoms of beriberi and central nervous disorders occur, so it is necessary to ingest them from pharmaceuticals, quasi-drugs and foods. Vitamin B1 is formulated in many products such as oral liquid-type vitamin-containing health supplements taken for the purpose of nutritional supplementation during physical fatigue, and soft drinks that can supply one-day nutrients, contributing to the nutritional supplementation of the general public. On the other hand, vitamin B1s are known to decompose in solution and generate a peculiar unpleasant odor similar to that of rotten eggs, making it difficult to develop products with excellent palatability from the perspective of flavor.

[0003] In order to solve such problems, a method (Patent Document 1) of containing limonene and nootkatone, which are often contained in citrus fruits, to suppress the unpleasant odor peculiar to vitamin B1 is known. Also known is a method (Patent Document 2) of preventing the generation of off-flavor components due to the decomposition of vitamin B1 by containing a tea extract in a vitamin B1-containing acidic drinking composition. However, in both cases, the flavor of the product is limited, resulting in low versatility and a demand for further technological improvement.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

Summary of the Invention

[0005] The present invention provides an oral liquid composition containing vitamin B1 or its derivatives or salts thereof, in which the unpleasant odor derived from vitamin B1 is reduced. [Means for solving the problem]

[0006] As a result of diligent research to solve the above problems, the inventors have found that by incorporating an extract from the rhizome of galangal (Alpinia galanga L.), a plant of the ginger family, or an extract from the leaves of mango (Mangifera indica L.), a plant of the sumac family, into a composition containing vitamin B1, the unpleasant odor derived from vitamin B1 can be reduced. In other words, the present invention is as follows: (1) An oral liquid composition characterized by containing one or more selected from the group consisting of vitamin B1 and galangal extract and mango leaf extract. (2) The oral liquid composition described in (1), wherein the concentration of vitamin B1 is 0.0001 to 0.05% by mass. (3) The oral liquid composition according to (1) or (2), wherein the concentration of galangal extract is 0.001 to 10% by mass on a dry solids basis. (4) An oral liquid composition according to any one of (1) to (3), wherein the concentration of mangiferin is 0.001 to 10% by mass. (5) An oral liquid composition according to any of (1) to (4) wherein the pH is 2.0 to 7.0. (6) An oral liquid composition according to any of (1) to (5), wherein the oral liquid composition is a liquid beverage. (7) An oral liquid composition according to any one of (1) to (6), wherein the content of galangal extract as dry solids per 1 part by mass of vitamin B1 is 0.02 to 100,000 parts by mass. (8) An oral liquid composition according to any one of (1) to (7), wherein the content of mangiferin per 1 part by mass of vitamin B1 is 0.02 to 100,000 parts by mass. (9) A method for suppressing the unpleasant odor of vitamin B1 in an oral liquid composition containing vitamin B1 by including galangal extract and / or mango leaf extract. [Effects of the Invention]

[0007] The present invention makes it possible to provide an oral liquid composition containing vitamin B1 compounds in which the unpleasant odor derived from vitamin B1 compounds is reduced. [Modes for carrying out the invention]

[0008] In the present invention, vitamin B1 refers to vitamin B1 or its derivatives or salts thereof, which are usually edible. Examples include thiamine, dicethiamine, fursultiamine, thiamine disulfide, bisbentiamine, bisibthiamine, benfotiamine, sicotiamine, octotiamine, prosultiamine, and salts thereof. Salts used in the present invention include nitrates, hydrochlorides, and sulfates, and preferably nitrates or hydrochlorides.

[0009] In the present invention, the vitamin B1 content in the oral liquid composition of the present invention is preferably 0.0001% to 0.05% by mass, more preferably 0.0005% to 0.05% by mass, 0.0005% to 0.02% by mass, 0.001% to 0.02% by mass, and 0.001% to 0.01% by mass, in that order, and particularly preferably 0.001% to 0.005% by mass.

[0010] The galangal extract in this invention is obtained by extracting the rhizome of galangal (Alpinia galanga L.), a plant of the genus Alpinia in the family Zingiberaceae (sometimes also called galanga or nankyo), either as is or after drying, crushing, or grinding as necessary. In other words, the galangal extract in this invention is an extract of the galangal rhizome. Note that galangal is different from black ginger, a plant of the genus Curcuma in the family Zingiberaceae, and turmeric, a plant of the genus Curcuma in the family Zingiberaceae.

[0011] The extraction method is not particularly limited and may be carried out by known extraction methods such as stirring, shaking, and immersion extraction using an organic solvent such as ethanol, water, or a mixture thereof, or by vacuum steam distillation extraction. If necessary, insoluble matter may be removed by centrifugation, enzymatic treatment (treatment with enzyme preparations derived from Aspergillus oryzae or Aspergillus oryzae), column or filtration (filtration using a strainer mesh or membrane filter, etc.). In the present invention, water and / or alcohol are preferably used as the extraction solvent for the galangal extract, ethanol is more preferably used as the alcohol, and water alone is particularly preferred. The extract obtained by extraction as described above may be used in liquid form, or it may be used in dried powder form. Commercially available powdered products (such as enXtra from Enovate Biolife) are also available. TM You may also use (etc.).

[0012] In the present invention, the galangal extract content is preferably 0.001% to 10% by mass in the oral liquid composition of the present invention, expressed as the dry solid content of the galangal extract, with the following being more preferable in that order: 0.001% to 1% by mass, 0.005% to 1% by mass, 0.005% to 0.6% by mass, 0.01% to 0.6% by mass, 0.02% to 0.6% by mass, 0.03% to 0.6% by mass, 0.03% to 0.6% by mass, 0.03% to 0.45% by mass, 0.04% to 0.45% by mass, 0.05% to 0.45% by mass, and 0.05% to 0.3% by mass, with 0.06% to 0.3% by mass being particularly preferable. In the present invention, "dry solid content" refers to the amount converted to the portion excluding water. Water can be measured using conventionally known methods such as heat drying or the Karl Fischer method.

[0013] Furthermore, the galangal extract content in the present invention, as an equivalent amount of galangal rhizome, is preferably 0.01% to 100% by mass in the oral liquid composition of the present invention, with the following being more preferable in order: 0.01% to 10% by mass, 0.05% to 10% by mass, 0.05% to 6% by mass, 0.1% to 6% by mass, 0.2% to 6% by mass, 0.3% to 6% by mass, 0.3% to 4.5% by mass, 0.4% to 4.5% by mass, 0.5% to 4.5% by mass, and 0.5% to 3% by mass, and particularly preferable is 0.6% to 3% by mass.

[0014] In the present invention, the amount of galangal extract taken orally per serving is preferably 10 mg to 1000 mg in the oral liquid composition of the present invention, calculated as the dry solid content of the galangal extract. The most preferred amounts are 10 mg to 500 mg, 50 mg to 500 mg, 50 mg to 400 mg, 50 mg to 300 mg, and 100 mg to 300 mg, in that order, with 150 mg to 300 mg being particularly preferred. In the present invention, "amount of oral intake per serving" refers to the amount of the oral liquid composition of the present invention taken at one time, more specifically, the amount taken intermittently or continuously over a short period of time, for example, about 30 minutes or less, for example, 50 mL to 500 mL.

[0015] In the oral liquid composition of the present invention, the mass ratio of vitamin B1 and galangal extract on a dry solids basis, that is, the content of galangal extract on a dry solids basis per 1 part by mass of vitamin B1, is preferably 0.02 parts by mass to 100,000 parts by mass, more preferably 0.02 parts by mass to 6,000 parts by mass, 0.4 parts by mass to 6,000 parts by mass, and 0.4 parts by mass to 3,000 parts by mass, in that order, and particularly preferably 1.2 parts by mass to 3,000 parts by mass.

[0016] In the oral liquid composition of the present invention, the mass ratio of vitamin B1 to the amount of galangal extract in terms of galangal rhizomes, that is, the amount of galangal extract in terms of galangal rhizomes per 1 part by mass of vitamin B1, is preferably 0.2 parts by mass to 1,000,000 parts by mass, more preferably 0.2 parts by mass to 60,000 parts by mass, 4 parts by mass to 60,000 parts by mass, and 4 parts by mass to 30,000 parts by mass, in that order, and particularly preferably 12 parts by mass to 30,000 parts by mass.

[0017] The mango leaf extract in this invention is obtained by extracting the leaves of the mango (Mangifera indica L.), a plant belonging to the Anacardiaceae family, either as is or, if necessary, after drying, crushing, grinding, or other processing. The extraction method is not particularly limited and may be carried out by known extraction methods such as stirring, shaking, and immersion extraction using an organic solvent such as ethanol, water, or a mixture thereof, or by vacuum steam distillation extraction. If necessary, insoluble matter may be removed by centrifugation, enzymatic treatment (treatment with enzyme preparations derived from Aspergillus oryzae or Aspergillus oryzae), column or filtration (filtration using a strainer mesh or membrane filter, etc.). In the present invention, commercially available mango leaf extracts (for example, Zynamite made of Nektium) may be used.

[0018] In addition, mango leaf extract usually contains mangiferin (1,3,6,7 - tetrahydroxyxanthone C2-β-D-glucoside), and the amount of mangiferin in the oral liquid composition may be used as an index for the content of mango leaf extract in the oral liquid composition. Mangiferin can be quantified using the method described in the section of the white tiger plus ginseng decoction extract in the eighteenth revised Japanese Pharmacopoeia. The amount of mangiferin is preferably 0.001% by mass to 10% by mass, more preferably 0.0024% by mass to 1% by mass, 0.012% by mass to 0.72% by mass, 0.036% by mass to 0.36% by mass in this order, and particularly preferably 0.06% by mass to 0.18% in the oral liquid composition of the present invention.

[0019] In the oral liquid composition of the present invention, the mass ratio of vitamin B1s to the amount of mangiferin, that is, the amount of mangiferin per 1 part by mass of vitamin B1s, is preferably 0.02 parts by mass to 100,000 parts by mass, more preferably 0.12 parts by mass to 10,000 parts by mass, 0.48 parts by mass to 7,200 parts by mass in this order, and particularly preferably 3 parts by mass to 1,440 parts by mass. The oral intake amount per time of the mango leaf extract in the present invention, in terms of the amount of mangiferin in the mango leaf extract, is preferably formulated at 0.5 mg to 50,000 mg in the oral liquid composition of the present invention, more preferably 5 mg to 5,000 mg, 12 mg to 1,000 mg, 12 mg to 360 mg in this order, and particularly preferably 60 mg to 360 mg.

[0020] The pH of the oral liquid composition of the present invention is not particularly limited, but is preferably 2.0 to 7.0, more preferably 2.0 to 4.5, further preferably 2.0 to 4.0, even more preferably 2.0 to 3.9, and particularly preferably 3.0 to 3.9 from the viewpoint of being suitable for drinking.

[0021] The pH of the oral liquid composition of the present invention can be adjusted using commonly used pH adjusting agents. Specific examples of pH adjusting agents include organic acids such as citric acid, malic acid, tartaric acid, succinic acid, lactic acid, acetic acid, maleic acid, gluconic acid, aspartic acid, adipic acid, glutamic acid, and fumaric acid, as well as their salts, inorganic acids such as hydrochloric acid, and inorganic bases such as sodium hydroxide. Preferred pH adjusting agents are citric acid, salts of citric acid, hydrochloric acid, and sodium hydroxide.

[0022] Furthermore, the oral liquid composition of the present invention may contain, as long as it does not impair the effects of the present invention, other components such as vitamins other than vitamin B1, minerals, amino acids or their salts, crude drugs, crude drug extracts, royal jelly, caffeine, etc., as appropriate.

[0023] Furthermore, the oral liquid composition of the present invention may contain additives such as antioxidants, colorants, fragrances, flavoring agents, surfactants, thickeners, stabilizers, preservatives, sweeteners, and acidulants, as long as they do not impair the effects of the present invention.

[0024] The oral liquid composition in this invention is not particularly limited as long as it is a liquid composition that can be taken orally, and includes pharmaceuticals, quasi-drugs, or foods (including foods with functional claims, foods with nutritional function claims, and foods for specified health uses). Examples of pharmaceuticals and quasi-drugs include oral solutions and drinks. Examples of foods include soft drinks, carbonated drinks, sports and functional drinks, non-alcoholic drinks, dairy drinks, tea drinks, coffee drinks, fruit and vegetable drinks, and jelly drinks.

[0025] The oral liquid composition of the present invention can be manufactured by conventionally known methods. For example, galangal extract or mango leaf extract and vitamin B1 compounds are added to water, and other components mentioned above are optionally added and dissolved. Further water is added to adjust the volume. If necessary, the pH is adjusted and heat sterilization is performed, and the mixture is filled into containers to provide an easily portable oral liquid composition.

[0026] When the oral liquid composition of the present invention is used to make a carbonated beverage, for example, galangal extract or mango leaf extract and vitamin B1 are added to water, and other components mentioned above are added and dissolved as desired to prepare a beverage stock. After adjusting the pH as necessary and performing heat sterilization, the mixture is cooled, carbon dioxide is injected under pressure (carbonation), the mixture is filled into containers, and sterilized as appropriate. The gas volume is preferably 0.5 to 4.0. The gas volume is the volume ratio of carbon dioxide dissolved in the solvent liquid 1 to the volume of the solvent liquid 1 at standard conditions (1 atmosphere, 20°C). There are two methods for producing carbonated beverages: the premix method and the postmix method, and either may be used in the present invention. [Examples]

[0027] The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited in any way to these examples. As vitamin B1 compounds, commercially available products such as thiamine nitrate manufactured by DSM, thiamine disulfide manufactured by Tokyo Chemical Industry Co., Ltd., fursultiamine hydrochloride manufactured by Watanabe Chemical Co., Ltd., and benfotiamine manufactured by Tokyo Chemical Industry Co., Ltd. were used. For mango leaf extract, Zynamite manufactured by Nektium was used in the following examples and comparative examples. (Extraction Examples 1 and 2, Examples 1-10, Comparative Examples 1-10)

[0028] Preparation of galangal extract: [Extraction Example 1: Hereinafter referred to as Galangal Extract A in this invention] Galangal rhizomes were extracted with hot water, and concentrated under reduced pressure using a conventional method to obtain a dry powder (solid) extract in an amount equal to one-tenth of the mass of the galangal rhizomes. [Extraction Example 2: Hereinafter referred to as Galangal Extract B in this invention] Galangal rhizomes were extracted with hot water, and then subjected to enzyme treatment, filtration, and vacuum concentration using conventional methods to obtain a liquid extract with a Brix of 15 (soluble solids content of 15%). In the table of the test examples, the amount of galangal extract A and B is listed on a basis of galangal dry solids.

[0029] Preparation of oral liquid compositions: Oral liquid compositions were prepared according to the formulations described in Tables 2-7 below and the following methods. First, thiamine nitrate, thiamine disulfide, fursultiamine hydrochloride, or benfotiamine was added to purified water and dissolved. The purified water was preheated to 70°C depending on the solubility of vitamin B1. Then, galangal extract A, galangal extract B, or mango leaf extract was added and thoroughly stirred. After stirring, the pH was adjusted using hydrochloric acid and sodium hydroxide solution, and purified water was added to make the total volume to obtain the oral liquid composition (Examples 1-10). Oral liquid compositions without galangal extract A, galangal extract B, or mango leaf extract were used as comparative examples (Comparative Examples 1-10).

[0030] The obtained oral liquid composition was filled into 30 ml screw-cap tubes No. 6 (manufactured by Maruemu Co., Ltd.) and sterilized at 80°C for 25 minutes. After sterilization, the prepared oral liquid composition was stored at 65°C for 7 days.

[0031] Evaluation of unpleasant odors derived from vitamin B1: As described above, the oral liquid composition stored at 65°C for 7 days was smelled, and the degree of reduction of unpleasant odor was evaluated according to the criteria in Table 1.

[0032] [Table 1]

[0033] [Table 2]

[0034] [Table 3]

[0035] [Table 4]

[0036] [Table 5]

[0037] [Table 6]

[0038] [Table 7]

[0039] As is clear from Tables 2-7, compositions containing vitamin B1 and galangal extract or mango leaf extract each showed an effect of reducing the unpleasant odor derived from vitamin B1 compared to the comparative example.

[0040] (Examples 11 and 12) Liquid beverages and carbonated beverages were prepared according to the formulations listed in Table 8 and the following methods.

[0041] Preparation of liquid beverages: In water comprising approximately 50% of the total volume, all components except riboflavin 5'-phosphate sodium and sodium benzoate were added and dissolved. To this, a solution containing approximately 10% of the total volume of 70°C water, in which riboflavin 5'-phosphate sodium and sodium benzoate were added and dissolved, was added and thoroughly stirred. After stirring, the pH was adjusted using trisodium citrate, and purified water was added to bring the total volume to obtain the oral liquid composition (Example 11). The obtained oral liquid composition was filled into 100 ml tea bottles, sealed, and sterilized at 80°C for 25 minutes. After sterilization, the prepared oral liquid composition was stored at 65°C for 7 days. The vitamin B1-derived unpleasant odor was evaluated according to the evaluation criteria in Table 1, as in Examples 1-10 and Comparative Examples 1-10.

[0042] Preparation of carbonated beverages: In water comprising approximately 10% of the total volume, all components except riboflavin 5'-phosphate sodium and sodium benzoate were added and dissolved. To this, a solution containing approximately 2.5% of the total volume of 70°C water, in which riboflavin 5'-phosphate sodium and sodium benzoate were added and dissolved, was added and thoroughly stirred. After stirring, the pH was adjusted using trisodium citrate, and water was added until the total volume reached 25% to prepare a beverage stock solution. This beverage stock solution was sterilized at 80°C for 25 minutes, carbonated water was added to reach the total volume, and 250 ml was filled into an aluminum can (Example 12). After filling, the prepared oral liquid composition was stored at 65°C for 7 days. The vitamin B1-derived unpleasant odor was evaluated according to the evaluation criteria in Table 1, as in Examples 1-10 and Comparative Examples 1-10.

[0043] [Table 8]

[0044] As is clear from Table 8, in Examples 11 and 12, it was confirmed that the unpleasant odor derived from vitamin B1 was only slightly noticeable. [Industrial applicability]

[0045] This invention makes it possible to suppress unpleasant odors when galangal extract and / or mango leaf extract and vitamin B1 are combined in an oral liquid composition. Therefore, it is expected that this invention will provide oral liquid compositions with excellent flavor and high marketability in the fields of pharmaceuticals, quasi-drugs, and food products.

Claims

1. An oral liquid composition characterized by containing vitamin B1 and mango leaf extract, wherein the concentration of vitamin B1 is 0.0001 to 0.05% by mass, and the content of mangiferin per 1 part by mass of vitamin B1 is 0.12 to 10000 parts by mass.

2. The oral liquid composition according to claim 1, wherein the pH is 2.0 to 7.

0.

3. The oral liquid composition according to claim 1 or 2, wherein the oral liquid composition is a liquid beverage.

4. A method for suppressing the unpleasant odor of vitamin B1 in an oral liquid composition containing vitamin B1, in which the concentration of vitamin B1 is 0.0001 to 0.05% by mass, by including 0.02 to 6000 parts by mass of galangal extract per 1 part by mass of vitamin B1, in terms of dry solid content.

5. A method for suppressing the unpleasant odor of vitamin B1 in an oral liquid composition containing vitamin B1, in which the concentration of vitamin B1 is 0.0001 to 0.05% by mass, by including mango leaf extract in an amount such that the mangiferin content is 0.12 to 10,000 parts by mass per 1 part by mass of vitamin B1.

Images